Literature DB >> 34484921

Immune Reconstitution Syndrome After Nivolumab for Progressive Multifocal Leukoencephalopathy.

Julien Haroche1, Fleur Cohen Aubart1, Karima Mokhtari1, Danielle Seilhean1, Neila Benameur1, Matthieu Peyre1, Ahmed Idbaih1, Zahir Amoura1.   

Abstract

Entities:  

Year:  2021        PMID: 34484921      PMCID: PMC8382340          DOI: 10.1212/CPJ.0000000000000811

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN: 2163-0402


× No keyword cloud information.
  6 in total

1.  A controlled inflammation and a regulatory immune system are associated with more favorable prognosis of progressive multifocal leukoencephalopathy.

Authors:  Nobuo Sanjo; Yurie Nose; Yukiko Shishido-Hara; Saneyuki Mizutani; Yoshiki Sekijima; Hitoshi Aizawa; Toru Tanizawa; Takanori Yokota
Journal:  J Neurol       Date:  2018-12-03       Impact factor: 4.849

2.  Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy.

Authors:  Irene Cortese; Pawel Muranski; Yoshimi Enose-Akahata; Seung-Kwon Ha; Bryan Smith; MariaChiara Monaco; Caroline Ryschkewitsch; Eugene O Major; Joan Ohayon; Matthew K Schindler; Erin Beck; Lauren B Reoma; Steve Jacobson; Daniel S Reich; Avindra Nath
Journal:  N Engl J Med       Date:  2019-04-10       Impact factor: 91.245

3.  Treatment of Progressive Multifocal Leukoencephalopathy with Pembrolizumab.

Authors:  Sebastian Rauer; Reinhard Marks; Horst Urbach; Klaus Warnatz; Avindra Nath; Steve Holland; Cornelius Weiller; Bodo Grimbacher
Journal:  N Engl J Med       Date:  2019-04-10       Impact factor: 91.245

4.  Treatment of Progressive Multifocal Leukoencephalopathy with Nivolumab.

Authors:  Ondine Walter; Emmanuel Treiner; Fabrice Bonneville; Catherine Mengelle; François Vergez; Fleur Lerebours; Pierre Delobel; Roland Liblau; Guillaume Martin-Blondel
Journal:  N Engl J Med       Date:  2019-04-10       Impact factor: 91.245

5.  Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

Authors:  Hussein A Tawbi; Peter A Forsyth; Alain Algazi; Omid Hamid; F Stephen Hodi; Stergios J Moschos; Nikhil I Khushalani; Karl Lewis; Christopher D Lao; Michael A Postow; Michael B Atkins; Marc S Ernstoff; David A Reardon; Igor Puzanov; Ragini R Kudchadkar; Reena P Thomas; Ahmad Tarhini; Anna C Pavlick; Joel Jiang; Alexandre Avila; Sheena Demelo; Kim Margolin
Journal:  N Engl J Med       Date:  2018-08-23       Impact factor: 91.245

6.  Progressive multifocal leukoencephalopathy treated with nivolumab.

Authors:  Ethan Hoang; Nancy L Bartlett; Manu S Goyal; Robert E Schmidt; David B Clifford
Journal:  J Neurovirol       Date:  2019-03-12       Impact factor: 2.643

  6 in total
  1 in total

Review 1.  Promise and Challenges of Checkpoint Inhibitor Therapy for Progressive Multifocal Leukoencephalopathy in HIV.

Authors:  Sydney Corey; Bryan R Smith; Irene C M Cortese
Journal:  Curr HIV/AIDS Rep       Date:  2022-10-01       Impact factor: 5.495

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.